Cancer therapy with chimeric antigen receptor (CAR)-T cells has achieved impressive remissions in certain hematologic malignancies, and extending the approach to other types of cancer is a key goal of immunotherapy research. Solid tumors have proved particularly challenging because of immunosuppressive mechanisms in the tumor microenvironment. Writing in Science, Danino and colleagues outline a new strategy for deploying CAR-T cells against solid tumors: use engineered bacteria to coat the interior of the tumor with a synthetic antigen and then treat with CAR-T cells specific for the synthetic antigen.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
About this article
Cite this article
Aschheim, K. A bacterial assist for CAR-T cells.
Nat Biotechnol41, 1521 (2023). https://doi.org/10.1038/s41587-023-02042-w
Download citation
Published: 10 November 2023
Issue Date: November 2023
DOI: https://doi.org/10.1038/s41587-023-02042-w
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02042-w
